-+ 0.00%
-+ 0.00%
-+ 0.00%

VERASTEM ONCOLOGY ANNOUNCES UPDATED DATA FROM PARTNER GENFLEET THERAPEUTICS’ PHASE 1 STUDY IN CHINA OF GFH375 (VS-7375), AN ORAL KRAS G12D (ON/OFF) INHIBITOR

Reuters·06/02/2025 13:40:00

Please log in to view news